Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 148

Sort by

Sort Order Select

Journal Articles

Impact of Treatment-Related Morbidity on Health-Related Quality of Life in Patients with Advanced-Stage Classical Hodgkin Lymphoma Receiving Multiagent Therapy: Findings from the HD21 Study

Fjoralba Kristo, Flora Mazerolle, Thibaud Alin, Antoine Regnault, Justin Ferdinandus, Karolin Behringer, Janina Jablonski, Peter Borchmann, Ajibade Ashaye

Blood (2024) 144 (Supplement 1): 4426.

https://doi.org/10.1182/blood-2024-200233

Published: 2024

Journal Articles

PRIMAVERA: A Modular Phase I/II Study to Evaluate the Safety, Tolerability, and Efficacy of AZD3470, a Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor, in Participants with Relapsed/Refractory Hematologic Malignancies

Blood (2024) 144 (Supplement 1): 1674.2.

https://doi.org/10.1182/blood-2024-203060

Published: 2024

Journal Articles

PET-Guided Brecadd in Older Patients with Advanced-Stage Classic Hodgkin Lymphoma: Results of the Phase 2 Part of the GHSG HD21 Trial

Blood (2024) 144 (Supplement 1): 568.

https://doi.org/10.1182/blood-2024-207946

Published: 2024

Journal Articles

Metabolic Tumor Volume after Two Cycles of Chemotherapy in Patients Treated for Advanced-Stage Hodgkin Lymphoma: Analysis of the German Hodgkin Study Group Phase III HD18 and HD21 Trials

Justin Ferdinandus, Helen Kaul, Gundolf Schneider, Michael Fuchs, Hans Theodor Eich, Christian Baues, Johannes Rosenbrock, Katrin S Roth, Alexander Drzezga, Lutz Van Heek, Markus Dietlein, Peter Borchmann, Carsten Kobe

Blood (2024) 144 (Supplement 1): 566.

https://doi.org/10.1182/blood-2024-210791

Published: 2024

Journal Articles

Abscopal Effect of Radiotherapy and Nivolumab in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma: Results of the International GHSG Phase II Aern Trial

Paul J. Bröckelmann, Ina Bühnen, Josée M Zijlstra, Stephan Mathas, Katrin S Roth, Maria Garcia-Marquez, Christian Sillaber, Julia Meissner, Alexander Fossa, Richard Greil, Karolin Trautmann-Grill, Johannes Rosenbrock, Wouter Plattel, Hans A Schlösser, Carsten Kobe, Michael Fuchs, Peter Borchmann, Christian Baues

Blood (2024) 144 (Supplement 1): 4428.

https://doi.org/10.1182/blood-2024-202113

Published: 2024

Journal Articles

Targeting Lymphoma Associated Myeloid-Monocytic Cells through CSF1R Blockade Enhances CAR-T Cell Response in Aggressive B Cell Lymphoma

Blood (2024) 144 (Supplement 1): 367.

https://doi.org/10.1182/blood-2024-203291

Published: 2024

Journal Articles

Brentuximab Vedotin, Cyclophosphamide, Doxorubicin and Prednisone (B-CAP) First-Line Treatment of Advanced-Stage Hodgkin Lymphoma: Final Results of the GHSG-NLG Phase II Bvb Trial

Paul J. Bröckelmann, Boris Böll, Daniel Molin, Gundolf Schneider, Sirpa Leppä, Julia Meissner, Peter Kamper, Martin Hutchings, Jacob Haaber Christensen, Ulf Schnetzke, Michael Fuchs, Dennis A Eichenauer, Bastian von Tresckow, Helen Kaul, Peter Borchmann, Alexander Fossa

Blood (2024) 144 (Supplement 1): 3054.

https://doi.org/10.1182/blood-2024-202120

Published: 2024

Journal Articles

Serum TARC Dynamics Correlate with Clinical Response and Metabolic Tumor Volume during Anti-PD1-Based First-Line HL Treatment in the GHSG Phase II Nivahl Trial

Paul J. Bröckelmann, Sophie Teesink, Lydia Visser, Conrad-Amadeus Voltin, Helen Kaul, Hans Schlösser, Bart-Jan Kroesen, Carsten Kobe, Peter Borchmann, Arjan Diepstra, Wouter Plattel

Blood (2024) 144 (Supplement 1): 3044.

https://doi.org/10.1182/blood-2024-201547

Published: 2024

Journal Articles

Estimation of Health State Utility Values for Patients Undergoing First-Line Treatment of Advanced-Stage Classical Hodgkin Lymphoma in the HD21 Trial

Christopher G. Pelligra, Fjoralba Kristo, Yutian Mu, Justin Ferdinandus, Karolin Behringer, Janina Jablonski, Peter Borchmann, Ajibade Ashaye

Blood (2024) 144 (Supplement 1): 2346.

https://doi.org/10.1182/blood-2024-200133

Published: 2024

Journal Articles

Lisocabtagene Maraleucel (liso-cel) in Patients (pts) with Relapsed or Refractory (R/R) Follicular Lymphoma (FL): Transcend FL 2-Year Follow-up

Blood (2024) 144 (Supplement 1): 4387.

https://doi.org/10.1182/blood-2024-198509

Published: 2024

Journal Articles

Patterns of Disease in Early Stage Favorable Hodgkins Lymphoma

Hishan Tharmaseelan, Janina Jablonski, Ina Bühnen, Johannes Rosenbrock, Paul J. Bröckelmann, Justin Ferdinandus, Peter Borchmann

Blood (2024) 144 (Supplement 1): 3050.

https://doi.org/10.1182/blood-2024-200035

Published: 2024

Journal Articles

Lymphovista HL - a Validated Assay for Genotyping and MRD Assessment in Hodgkin Lymphoma

Julia Mattlener, Justin Ferdinandus, Jessica Schneider, Julia K. Schleifenbaum, Max Freihammer, Olivia Käsgen, Hodgkin Lymphoma MRD Consortium, Helen Kaul, Gundolf Schneider, Peter Borchmann, Jan-Michel Heger, Sven Borchmann

Blood (2024) 144 (Supplement 1): 4355.

https://doi.org/10.1182/blood-2024-205034

Published: 2024

Journal Articles

Patient-Reported Chemotherapy-Induced Peripheral Neuropathy (CIPN) in Advanced-Stage Classical Hodgkin Lymphoma Treated with BrECADD and eBEACOPP in the HD21 Trial

Fjoralba Kristo, Flora Mazerolle, Thibaud Alin, Antoine Regnault, Justin Ferdinandus, Karolin Behringer, Janina Jablonski, Peter Borchmann, Ajibade Ashaye

Blood (2024) 144 (Supplement 1): 1662.

https://doi.org/10.1182/blood-2024-200211

Published: 2024

Journal Articles

Entirely noninvasive outcome prediction in central nervous system lymphomas using circulating tumor DNA

Blood (2024) 143 (6): 522–534.

https://doi.org/10.1182/blood.2023022020

Published: 2024

Includes: Supplemental data

Journal Articles

Favezelimab in Combination with Pembrolizumab in Patients with Anti-PD-1-Naive Relapsed or Refractory Classical Hodgkin Lymphoma: Updated Analysis of an Open-Label Phase 1/2 Study

Nathalie A. Johnson, David Lavie, Peter Borchmann, Gareth P. Gregory, Alex F. Herrera, Leonard Minuk, Vladan Vucinic, Philippe Armand, Abraham Avigdor, Robin Gasiorowski, Yair Herishanu, Colm Keane, John Kuruvilla, Rachel Marceau West, Pallavi Pillai, Patricia Marinello, John Timmerman

Blood (2023) 142 (Supplement 1): 1693.

https://doi.org/10.1182/blood-2023-182128

Published: 2023

Journal Articles

Systematic Literature Review to Identify Influencing Factors of Efficacy and Safety Outcomes of Chimeric Antigen Receptor T-Cell Therapies in Large B-Cell Lymphoma

Jan-Michel Heger, Jonas Jost, Sybille Riou, Stefan Walzer, Joerg Mahlich, Peter Borchmann

Blood (2023) 142 (Supplement 1): 6288.

https://doi.org/10.1182/blood-2023-174916

Published: 2023

Journal Articles

Pregnancies and Childbirth Following Advanced-Stage Hodgkin Lymphoma Treatment with Brecadd or Beacopp in the Randomized Phase III GHSG HD21 Trial

Blood (2023) 142 (Supplement 1): 4437.

https://doi.org/10.1182/blood-2023-188449

Published: 2023

Journal Articles

Correlation between Progression-Free Survival and Overall Survival in Patients with Relapsed Hodgkin Lymphoma: An Analysis of Individual Patient Data from Randomized GHSG Trials

Paul J Bröckelmann, Horst Müller, Sarah Gillessen, Anne Sophie Jacob, Jesko Momotow, Carla Damaschin, Justin Ferdinandus, Xiaoqin Yang, Michael Fuchs, Carsten Kobe, Hans Theodor Eich, Andreas Engert, Peter Borchmann, Bastian von Tresckow

Blood (2023) 142 (Supplement 1): 3070.

https://doi.org/10.1182/blood-2023-188622

Published: 2023

Journal Articles

Favezelimab (anti-LAG-3) Plus Pembrolizumab in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Cohort 3 of a Multicohort Open-Label Phase 1/2 Study

Armando Santoro, Nathalie A. Johnson, Kerry J. Savage, Abraham Avigdor, Ali Bazargan, Peter Borchmann, Robin Gasiorowski, Gareth P. Gregory, Yair Herishanu, Sumit Madan, Leonard Minuk, Gerardo Musuraca, Rachel Marceau West, Pallavi Pillai, Patricia Marinello, Pier Luigi Zinzani

Blood (2023) 142 (Supplement 1): 1725.

https://doi.org/10.1182/blood-2023-182536

Published: 2023

Journal Articles

Comprehensive Analysis of Treatment Related Morbidity and Progression -Free Survival in the GHSG Phase III HD21 Trial

Blood (2023) 142 (Supplement 1): 3057.

https://doi.org/10.1182/blood-2023-188720

Published: 2023

NARROW

Impact of Treatment-Related Morbidity on Health-Related Quality of Life in Patients with Advanced-Stage Classical Hodgkin Lymphoma Receiving Multiagent Therapy: Findings from the HD21 Study

PRIMAVERA: A Modular Phase I/II Study to Evaluate the Safety, Tolerability, and Efficacy of AZD3470, a Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor, in Participants with Relapsed/Refractory Hematologic Malignancies

PET-Guided Brecadd in Older Patients with Advanced-Stage Classic Hodgkin Lymphoma: Results of the Phase 2 Part of the GHSG HD21 Trial

Metabolic Tumor Volume after Two Cycles of Chemotherapy in Patients Treated for Advanced-Stage Hodgkin Lymphoma: Analysis of the German Hodgkin Study Group Phase III HD18 and HD21 Trials

Abscopal Effect of Radiotherapy and Nivolumab in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma: Results of the International GHSG Phase II Aern Trial

Targeting Lymphoma Associated Myeloid-Monocytic Cells through CSF1R Blockade Enhances CAR-T Cell Response in Aggressive B Cell Lymphoma

Brentuximab Vedotin, Cyclophosphamide, Doxorubicin and Prednisone (B-CAP) First-Line Treatment of Advanced-Stage Hodgkin Lymphoma: Final Results of the GHSG-NLG Phase II Bvb Trial

Serum TARC Dynamics Correlate with Clinical Response and Metabolic Tumor Volume during Anti-PD1-Based First-Line HL Treatment in the GHSG Phase II Nivahl Trial

Estimation of Health State Utility Values for Patients Undergoing First-Line Treatment of Advanced-Stage Classical Hodgkin Lymphoma in the HD21 Trial

Lisocabtagene Maraleucel (liso-cel) in Patients (pts) with Relapsed or Refractory (R/R) Follicular Lymphoma (FL): Transcend FL 2-Year Follow-up

Patterns of Disease in Early Stage Favorable Hodgkins Lymphoma

Lymphovista HL - a Validated Assay for Genotyping and MRD Assessment in Hodgkin Lymphoma

Patient-Reported Chemotherapy-Induced Peripheral Neuropathy (CIPN) in Advanced-Stage Classical Hodgkin Lymphoma Treated with BrECADD and eBEACOPP in the HD21 Trial

Entirely noninvasive outcome prediction in central nervous system lymphomas using circulating tumor DNA

Favezelimab in Combination with Pembrolizumab in Patients with Anti-PD-1-Naive Relapsed or Refractory Classical Hodgkin Lymphoma: Updated Analysis of an Open-Label Phase 1/2 Study

Systematic Literature Review to Identify Influencing Factors of Efficacy and Safety Outcomes of Chimeric Antigen Receptor T-Cell Therapies in Large B-Cell Lymphoma

Pregnancies and Childbirth Following Advanced-Stage Hodgkin Lymphoma Treatment with Brecadd or Beacopp in the Randomized Phase III GHSG HD21 Trial

Correlation between Progression-Free Survival and Overall Survival in Patients with Relapsed Hodgkin Lymphoma: An Analysis of Individual Patient Data from Randomized GHSG Trials

Favezelimab (anti-LAG-3) Plus Pembrolizumab in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Cohort 3 of a Multicohort Open-Label Phase 1/2 Study

Comprehensive Analysis of Treatment Related Morbidity and Progression -Free Survival in the GHSG Phase III HD21 Trial

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only